五价锑治疗印度内脏利什曼病失败：来自印度疫情中心的报告
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
作者信息
Sundar S, More D K, Singh M K, Singh V P, Sharma S, Makharia A, Kumar P C, Murray H W
机构信息
The Kala-Azar Medical Research Center, Banaras Hindu University Institute of Medical Sciences, Varanasi, India.
出版信息
Clin Infect Dis. 2000 Oct;31(4):1104-7. doi: 10.1086/318121.
In India, 320 patients with visceral leishmaniasis (209 in the state of Bihar and 11 in the neighboring state of Uttar Pradesh) received identical pentavalent antimony (Sb) treatment. Sb induced long-term cure in 35% (95% confidence interval [CI], 28%-42%) of those in Bihar versus 86% (95% CI, 79%-93%) of those in Uttar Pradesh. In Bihar, the center of the Indian epidemic, traditional Sb treatment should be abandoned.
在印度，320名内脏利什曼病患者（比哈尔邦209例，邻近的北方邦11例）接受了相同的五价锑（Sb）治疗。在比哈尔邦，Sb使35%（95%置信区间[CI]，28%-42%）的患者获得长期治愈，而在北方邦这一比例为86%（95%CI，79%-93%）。在印度疫情的中心比哈尔邦，应摒弃传统的锑治疗方法。
Zotero 插件